Phage International, Inc.
Danville, CA USA
Beginning in the 1940's G.Eliava Institute of Bacteriophage, Microbiology and Virology produced several types of bacteriophage-based treatments. In 1994 the production group at this Institute separated from the Eliava Institute and formed a new commercial company, JSC Biochimpharm.
JSC proceeded to restore mass production of several classic phage preparations, rennovating the bacterial strain and phage collections, and enhanced these products to address newly emerging antibiotic resistant strains.
Despite a recent history grave economic and political conditions, Biochimpharm now mass produces of two highly effective polyvalent bacteriophage preparations and several monophage preparations. Biochimpharm's manufacturing capabilities are the world's best in terms of quality, consistency and capacity.
Ludwik Hirszfeld Institute of Immunology and Experimental Therapy
Polish Academy of Science - Wroclaw, Poland
Recent human clinical studies performed at Herzfeld Institute, Polish Academy of Sciences